(Q77359704)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

title

Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

author name string

E A Omar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

H Behlouli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

S Chevalier

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

A G Aprikian

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

publication date

1 November 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

page(s)

191-199

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation

5 December 2019

cites work

1 reference

Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy.

21 January 2018

1 reference

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

21 January 2018

1 reference

p53 mutations in human cancers

21 January 2018

1 reference

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression

21 January 2018

1 reference

Overexpression of p53 and prognosis in breast cancer

21 January 2018

1 reference

Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response

21 January 2018

1 reference

Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma

21 January 2018

1 reference

p53 protein accumulation and gene mutation in the progression of human prostate carcinoma

21 January 2018

1 reference

p53 gene alterations in human prostate carcinoma.

21 January 2018

1 reference

Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer

21 January 2018

1 reference

p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis

21 January 2018

1 reference

The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy

21 January 2018

1 reference

Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation

21 January 2018

1 reference

Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: a retrospective immunohistochemical analysis

21 January 2018

1 reference

p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy

21 January 2018

1 reference

Cell cycle control and cancer

21 January 2018

1 reference

p21 is a universal inhibitor of cyclin kinases

21 January 2018

1 reference

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism

21 January 2018

1 reference

The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma

21 January 2018

1 reference

p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction

21 January 2018

1 reference

Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma

21 January 2018

1 reference

Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy

21 January 2018

1 reference

Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer

21 January 2018

1 reference

Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression

21 January 2018

1 reference

Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations

21 January 2018

1 reference

Frequency and characterization of p53 mutations in clinically localized prostate cancer

21 January 2018

1 reference

p53 oncogene mutations in human prostate cancer specimens

21 January 2018

1 reference

p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate

21 January 2018

1 reference

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

21 January 2018

1 reference

p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma.

21 January 2018

1 reference

A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers

21 January 2018

1 reference

Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma

21 January 2018

1 reference

The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma

21 January 2018

1 reference

Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa).

21 January 2018

1 reference

Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PROS.1134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11746264%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference